Frailty is common in older patients undergoing percutaneous coronary intervention (PCI) in the US, with a “clear gradient of increasing risk” based on frailty status, according to a new registry analysis of more than 1.3 million patients.
A review redefines heart failure with improved ejection fraction (HFimpEF) as a distinct clinical phenotype with persistent risks despite apparent recovery in heart function.
Patients with the coronavirus disease 2019 (COVID-19) have long-term reduced stress perfusion, indicative of coronary microvascular dysfunction (CMD) and reduced left ventricular (LV) function, compared with healthy patients, a new case-control study shows.
A new database analysis of Evoque system usage in patients undergoing transcatheter tricuspid valve replacement reveals several adverse cardiovascular events not reported in the original trial for approval of the system.
New research has found that using advanced calcific plaque modification devices (ACPMDs) significantly improves outcomes in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) with severe calcification.
New study findings reveal that assessing right ventricular–pulmonary artery coupling (RVPAC) helps predict which patients with severe tricuspid regurgitation (TR) could benefit from transcatheter tricuspid valve edge-to-edge repair (T-TEER).
New research findings point to the safety and efficacy of a novel heterotopic valve device designed to treat patients with severe tricuspid regurgitation (TR) who are ineligible for traditional surgical or interventional approaches: the Trillium Device.
A new analysis reveals that patients with heart failure with improved ejection fraction (HFimpEF) remained at high risk of cardiovascular events, as researchers emphasized the condition’s continued management despite left ventricular EF (LVEF) improvement, but finerenone may mitigate this risk.
Patients undergoing left atrial appendage occlusion (LAAO) with a Watchman device may experience a significantly lower risk of early device-related thrombus (DRT) when managed with low-dose direct oral anticoagulation (LD-DOAC) compared to dual antiplatelet therapy (DAPT).
Patent foramen ovale (PFO) closure reduces the risk of recurrent ischemic stroke for older patients compared with medical therapy alone, according to a new real-world analysis of Medicare beneficiaries.
Bailey G. Salimes, CRTonline.org
Natalie Morrison, CRTonline.org
Will Chu, CRTonline.org
Michael Mahmoudi, MD - C Terkelsen, et al.; Lancet 2025; 405:1362-1372
Michael Mahmoudi, MD - X Hu, et al.; Lancet 2025; 405:1491-1504
Michael Mahmoudi, MD - W Fearon, et al.; Lancet 2025; 405:1481-1490
Michael Mahmoudi, MD - S Nissen, et al.; NEJM 2025 Online
BUSINESS WIRE
HighLife
PRNewswire
GLOBE NEWSWIRE
Do you think there is a role for embolic protection devices in patients undergoing TAVR?
Yes
No
Only on a subset of patients
Sahib Singh, Muhammad Asim Shabbir, Nidhish Tiwari, Kevin Bliden, Udaya S. Tantry, Paul A. Gurbel, Mohammed Y. Kanjwal and Scott W. Lundgren
Abhishek Chaturvedi, Gregg W. Stone, Jason Galo, Akiko Maehara, Ziad A. Ali, Evan Shlofmitz, Dan Haberman, Adnan Kastrati, Christos V. Bourantas, Gary S. Mintz and Ron Waksman
Sean DeAngelo, Badri Aryal, Gianfranco Bittar-Carlini, Rohan Gajjar, Jeremiah Bello, Sharan Malkani, Ufuk Vardar and Abhimanyu Saini
Michail Penteris
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details